- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.10. | Kairos Pharma, Ltd: Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting | 793 | Business Wire | Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safety data
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage... ► Artikel lesen | |
| 15.10. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Kairos Pharma stock rises after selection for ESMO Congress presentation | 2 | Investing.com | ||
| 07.10. | Kairos Pharma präsentiert Daten zu Prostatakrebs-Therapie auf ESMO-Kongress | 3 | Investing.com Deutsch | ||
| 07.10. | Kairos Pharma, Ltd: Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025 | 259 | Business Wire | Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to... ► Artikel lesen | |
| 07.10. | Kairos Pharma, LTD. - 8-K, Current Report | 5 | SEC Filings | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | Kairos Pharma stock gains as H.C. Wainwright reiterates Buy rating | 1 | Investing.com | ||
| 18.09. | Kairos Pharma meldet vielversprechende Studiendaten zu Prostatakrebs-Therapie | 1 | Investing.com Deutsch | ||
| 18.09. | Kairos Pharma reports promising interim data for prostate cancer therapy | 3 | Investing.com | ||
| 18.09. | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.09. | Kairos Pharma präsentiert erste Phase-1-Daten zu Lungenkrebs-Medikament auf Fachkonferenz | 2 | Investing.com Deutsch | ||
| 03.09. | Kairos Pharma to present initial phase 1 data for lung cancer drug at conference | 3 | Investing.com | ||
| 03.09. | Kairos Pharma, Ltd: Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 | 255 | Business Wire | Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data... ► Artikel lesen | |
| 03.09. | Kairos Pharma, LTD. - 8-K, Current Report | 4 | SEC Filings | ||
| 15.08. | Interview: Kairos Pharma CEO John Yu on ENV105's potential & partnerships for growth | 3 | iNVEZZ.com | ||
| 12.08. | Kairos Pharma, LTD. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.07. | Kairos Pharma, LTD. - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 28.07. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline | 483 | Newsfile | Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 15.07. | Why Is Kairos Pharma Stock Surging On Tuesday? | 2 | Benzinga.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,91 | -0,09 % | Biotech-Boom: Novartis übernimmt Avidity Biosciences für 12 Milliarden US$ | Der Schweizer Pharmakonzern Novartis hat einen bedeutenden Schritt in der Erweiterung seines Portfolios gemacht. Mit der Übernahme des US-Biotechnologieunternehmens Avidity Biosciences stärkt Novartis... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,290 | +0,50 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| QIAGEN | 41,140 | -1,72 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,010 | +27,34 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,520 | +2,04 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 199,36 | +6,71 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,320 | +0,67 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,970 | -2,52 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital | ||
| EVOTEC | 7,074 | -0,70 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,910 | -6,04 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| INTELLIA THERAPEUTICS | 11,975 | -3,85 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| JANUX THERAPEUTICS | 29,760 | +8,77 % | Janux Therapeutics gains amid renewed takevover speculation | ||
| ADMA BIOLOGICS | 15,600 | -0,03 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 556,80 | +10,21 % | Paradigmenwechsel in der Glaukommedizin? NurExone erzielt dosisabhängige Wiederherstellung des Sehvermögens |
KAIROS PHARMA LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,005 (+0,44 %) liegt der Kurs bei 1,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.